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Abstract  
In recent years, the anti-leukemic potential of Natural Killer (NK) cells and their 
role in hematologic malignancies and in Hematopoietic Stem Cell Transplants (HSCT) 
has attracted greater interest and a recent study by Cooley S. et al. showed a better 
clinical outcome when patients with Acute Myeloid Leukemia received a transplant 
from unrelated Group B KIR haplotypes donors. As a consequence of these results, an 
algorithm called "KIR B-content score" was formulated, based on the number of 
centromeric and telomeric Group B KIR haplotypes gene-content motifs. The KIR B-
content score defines three categories of donors: Neutral donors have none or one KIR 
B motifs, Better donors have two or more B motifs without KIR Cen B/B and Best 
donors have two or more B motifs with KIR Cen B/B. The aim of our research is a 
retrospective analysis of HSC unrelated transplants performed in our center to analyze 
the effect of the donor KIR B status on the clinical-outcome. Our results showed a better 
overall survival-rate in the AML recipients, HLA mismatched with the donor, when the 
donor KIR B content status is Best/Better (37% vs 18% at three years P=0,028), 
whereas there is no beneficial effect for recipients with other haematological 
malignancies. Moreover, we observed that AML recipients, whose Donors KIR B status 
was Best/Better, had more incidence of aGvHD grade I II than patients whose Donors 
KIR B status was Neutral (70% vs 26%) and also a lower rate of relapse (36% vs 58%) 
and a better Disease Free Survival-rate (58% vs 38% at three years P=0,1) because of 
a better GvL effect. 
 
Keywords: UDHSCT, NK Cells, Donor KIR B Status, AML,  GvL effect.  
4 
 
1. Introduction 
1.1 Hematopoietic stem cell transplantation (HSCT) 
 Hematopoietic stem cell transplantation (HSCT) has emerged as one of the most 
useful therapeutic strategies in the treatment of hematologic malignancies (acute or 
chronic myeloid or lymphoid leukemia) or hereditary (Thalassemia Major) for which 
conventional therapies offer little or no chance of cure. HSCT consists in the 
replacement of the diseased or non-functional bone marrow with healthy stem cells 
capable of regenerating all blood cells and restoring the normal hematologic and 
immunologic functions. The source of Hematopoietic Stem Cells (HSC) can be Bone 
Marrow (BMT), Peripheral Blood after appropriate stimulation (PBHSCT) or Cord 
Blood (CBHSCT). The transplant can be autologous (the patient's own HSC transplant 
after suitable treatment) or allogeneic (HSC transplant from a healthy donor). In the 
latter case it is essential to find a donor with genetic characteristics similar to those of 
the receiver because one of the most important variables that influence the success of 
HSCT is the compatibility of the genes of the HLA system. The Class I and II HLA 
matching between donor and recipient is crucial to prevent alloreactivity and, 
consequently, rejection, graft failure and, above all, the graft versus host disease 
(GVHD), because the transplanted cells from the donor are immunologically competent 
and can attack cells and tissues of the recipient [1-3].  
A very important aspect of the HSC transplant is the Graft versus Leukemia 
effect (GvL), which is a GvHD directed toward the leukemic cells: donors’ T 
lymphocytes attack the cells of the tissues causing GvHD but they can also attack and 
eliminate residual leukemic cells [4]. If the donor-recipient HLA compatibility is high, 
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the GvL effect is low, consequently, the possibility of relapse is high; on the contrary, 
when the HLA compatibility is low, the GvHD reaction will be great. A major 
challenge in improving the success of allogeneic hematopoietic stem cells in the 
treatment of leukemia is to minimize GvH reactions and simultaneously preserve and 
optimize GvL reactions. It has also been demonstrated that the GvL effect may be 
mediated by NK cells [5].  
It has been shown that only 25% of patients who need a HSC transplant find an 
HLA-identical sibling donor; the remaining 75% do not have an HLA-identical donor in 
their own family; in this case the alternative is to look for a HLA-matched, unrelated 
volunteer donor (MUD Matched Unrelated Donor) in the worldwide register of bone 
marrow donors. If there is no compatible donor, the choice of the haploidentical donor 
is a viable alternative, because there might often be half-identical donors such as parents 
or siblings [6]. Recently, the number of so-called alternative donor transplants, MUD 
and haploidentical transplants with one or more HLA mismatches, has significantly 
increased. This is due to the rise in the average age of the patients and therefore the 
impossibility of finding a compatible donor in their own family. For this reason research 
has steered toward the study of factors other than HLA matching, which could have a 
positive influence on the outcome of the transplants, including the role of Natural Killer 
(NK) cells in hematopoietic stem cell transplants and, consequently, the study of KIR 
genes. 
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1.2 Natural Killer Cells and KIR receptors 
The human NK cells are a part of the immune system with an important role in 
the host’s defense against infections from pathogens and in "immune surveillance" 
against cancer cells. Their function depends on several families of activating and 
inhibitory receptors including KIR receptors (killer-cell immunoglobulin-like 
receptors). The "missing-self" concept [7, 8], put forward by Karré and colleagues in the 
1980s, formed the basis for understanding the mechanisms of the action of NK cells 
(Figure 1).  According to this hypothesis the function of NK cells is to recognize and 
kill autologous cells which are deficient in MHC class I expression, a frequent event in 
tumour or virus-infected cells. 
 
 
Figure 1. “Missing-self hypothesis" explains the mechanism of action of NK Cells. 
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KIRs belong to the immunoglobulin super-family and are structurally 
characterized by two or three extracellular immunoglobulin-like domains. KIRs 
recognize the MHC class I molecules such as HLA-A, HLA-B and HLA-C. There are 
two distinct groups of KIRs: inhibitors and activators. The family of KIR genes, located 
on chromosome 19q13.4, includes 15 different loci [9]. Receptors are monomeric 
(single chain) with two (KIR2D) or three (KIR3D) immunoglobulin domains, which 
can be further divided into those with a long (Long) cytoplasmic tail (KIR2DL and 
KIR3DL) and those with a short (Short) one (KIR2DS and KIR3DS). The short tail 
generates an activation signal, while the long one generates an inhibition signal (Figure 
2). Each group has the same extracellular domain, and consequently each group binds 
the same ligands. However, due to differences in their transmembrane and intracellular 
domains, a group of KIRs determines an inhibitory response, while the other group 
determines an activating response [10].  KIR receptors and their ligands are summarized 
in Table 1. 
 
Figure 2. The inhibitory signal results from the presence of the long cytoplasmic tail containing tyrosine 
inhibitors motifs (ITIM: "immunoreceptor Tyrosine-based Inhibition Motifs"); the activating signal 
results from the presence of the short cytoplasmic tail containing tyrosine activation motifs (ITAM: 
"Immunoreceptor Tyrosine-based Activation Motifs"). Figure based on [10]. 
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       Table 1. KIR Receptors and their Ligands. 
 
In normal cells the expression of MHC class I molecules and their binding to 
NK inhibitory receptors inhibits the lysis, while in the virus-infected or cancer cells the 
lack of expression of self MHC molecules determines their susceptibility to lysis 
mediated by NK cells. In tumour or virus infected cells, stress-induced molecules are 
expressed on the cell surface and are recognized by the activating receptors that enhance 
the lysis. NK cells can also lyse allogeneic cells expressing HLA class I antigens that 
are not recognized by their inhibitory NK receptors. 
The KIR genes are polymorphic in humans and there are different allelic 
variants; each individual possesses his own KIRs repertoire depending on the allelic 
variants possessed. Different haplotypes contain a different number of KIR genes; some 
have only one or a few activating receptors, others have more activating receptors. In 
humans, two groups of KIR haplotypes have been identified, A and B, based on the 
content of different KIR genes. Haplotypes of group A are present in the entire 
population and consist of six KIR inhibitory genes KIR3DL3, KIR2DL3, KIR2DL1, 
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KIR2DL4, KIR3DL1, KIR3DL2 and one activator KIR2DS4, which is often present in 
a null allele variant that is not expressed on the cell surface. Group B comprises 
haplotypes with a different genetic content including genes KIR2DS2, KIR2DL2, 
KIR2DL5, KIR2DS3, KIR2DS1, KIR2DS5, and KIR3DS1, which are not part of the 
haplotypes of Group A. As a consequence, many haplotypes in Group B encode for a 
greater number of activating receptors compared to haplotypes in Group A (Figure 3).  
All individuals can be classified on the basis of the two KIR genotypes 
possessed: A/A, which is homozygous for the haplotypes of Group A, B/x, which 
contains one (heterozygous A/B) or two haplotypes of Group B (homozygous B/B). 
Individuals B/x possessing a larger number of activating receptors theoretically should 
have a better response against cancer or virus-infected cells. 
 
Figure 3. The organization of genes in the KIR locus. The centromeric and telomeric regions are 
separated by a unique recombination site (RS) sequence that can function to reassort the centromeric and 
telomeric gene motifs. 3DL3, 3DP1, 2DL4 and 3DL2 are conserved framework genes. B haplotype genes 
are orange, and A haplotype genes are blue. Figure based on [14]. 
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1.3 Role of NK Cells in HSCT 
In recent years, the anti-leukemic potential of Natural Killer (NK) cells and their 
role in hematologic malignancies and in HSCT has been attracting ever greater interest; 
however, it has not yet been clearly established whether the typing of KIR genes may be 
a useful tool in the selection of an HSC donor to promote a better outcome of the 
transplant [11]. 
The beneficial GvL effect, promoted by allo-reactive NK cells derived from the 
donor, was demonstrated for the first time in the HSC haploidentical transplants in 
patients with acute myeloid leukemia (AML); the best donor is NK mismatched with 
the recipient and therefore the donor’s KIRs do not recognize HLA class I molecules 
expressed by the host. In this way the donor’s NK cells are responsive to the direction 
GvH and this results in a better anti-leukemic effect with a better overall survival-rate 
and a lower rate of relapse of leukemia [12]. 
More recently, Cooley S. et al. [13] have demonstrated that AML patients who 
received HSC transplants from unrelated Group B KIR haplotype donors, had a better 
outcome after transplant, whereas recipient KIR genotype had no effect. The clinical 
outcome was better when the donors had one or two KIR B haplotypes (KIR B/x 
donors) rather than donors who had two KIR A haplotypes (KIR A/A donors); with a 
KIR B/x donor, relapse was reduced and the leukemia-free survival-rate (LFS) was 
increased. This is because the haplotypes of Group B have a larger number of activating 
receptors, and this translates into better anti-leukemic activity. A subsequent study [14] 
sought to determine whether the protective effect of KIR B could be mapped to either 
the centromeric or the telomeric region of the KIR locus. The centromeric region 
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contains genes encoding the inhibitory receptors for the C1 and C2 epitopes of HLA-C, 
whereas the telomeric region contains genes encoding the inhibitory receptors for the 
Bw4 and A3/11 epitopes and the activating C2 receptor (Table 2). It was found that 
both the centromeric and telomeric regions of KIR B correlated with protective effect, 
but the much stronger association was with the centromeric region. As a consequence of 
these results, an algorithm was formulated, called "KIR B-content score", based on the 
number of centromeric and telomeric Group B KIR haplotypes gene-content motifs. 
The KIR B-content score defines three categories of donors: Neutral donors have none 
or one KIR B motifs, Better donors have two or more B motifs without KIR Cen B/B 
and Best donors have two or more B motifs with KIR Cen B/B (Table 3). A calculator 
for classification of the donor KIR B status (Best, Better, Neutral) may be found at 
http://www.ebi.ac.uk/ipd/kir/.  
Recently, these results have been confirmed in HSCT from HLA-identical 
sibling donor [15]. Together, these results highlight the need for further studies of KIR 
polymorphisms, possibly at allelic level, to determine whether the typing of the donor 
KIR genes may be useful in donor selection for HSCT. 
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Table 2. Groups used for the Cen and Tel analysis on the basis of the content of the inhibitory 
(L-long)  or activating (S-short) KIR genes. Table based on [14] 
 
 
 
 
 
 
 
Table 3. KIR B–content score. The KIR B–content score is calculated by adding the number of 
Cen-B and/or Tel-B motifs in each genotype. Table based on [14] 
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2. Research aims 
The aim of our research is a retrospective analysis of HSC transplants performed 
at the Bone Marrow Transplant Unit (UTMO) of the “V. Cervello” Hospital in Palermo. 
The category of HSC transplants to be studied is the one from MUD. 
The objectives of this study are the following: 
1. Typing of the donors’ KIR genes of the transplants performed; 
2. Donors classification in  accordance with the KIR B Content Score in three 
categories: Neutral, Better, Best; 
3. Correlation of the Donor KIR B status with the clinical outcome of the 
transplants considering overall survival, the degrees of Graft versus Host 
Disease (GvHD) Graft versus Leukemia (GvL), Relapse and Disease Free 
Survival (DFS). 
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3. Materials and Methods 
3.1 Patient cohort 
We analyzed no. 89 patients, who received a URD HSCT between 1996 and 
2013. The median age of the 89 patients was 43 years (14-65). The transplanted patients 
had different hematological malignancies: 33 Acute Myeloid Leukemia (AML), 19 
Acute Limphoblastic Leukemia (ALL), 9 Myelodysplastic Syndromes (MDS), 6 Non 
Hodgkin Lymphoma (NHL), 6 Multiple Myeloma (MM), 5 Hodgkin Lymphoma (HL), 
4 Chronic Myeloid Leukemia (CML), 3 Chronic Lymphocytic Leukemia (CLL), 1 
Aplastic Anemia Syndrome (AAS), 1 Fanconi Syndrome, 1 Ematodermic Neoplasia, 1 
Biphenotypic Acute Leukemia (BAL). The HSC source was: Bone Marrow no. 19, 
Peripheral Blood no. 70. Complete high-resolution, allele-level HLA-A, B, C, DRB1 
and DQB1 typing of the 89 pairs of recipients and donors was previously performed: 32 
pairs were 10/10 matched, 33 pairs were 9/10 and 24 were ≤8/10. Patient and transplant 
characteristics are summarized in Tables 4 and 5. 
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               Table 4. Patient characteristics 
Median age (range)  43(14-65) 
Diagnosis 
AML  33 
ALL  19 
MDS  9 
NHL 6 
MM  6 
LH  5 
CML 4 
CLL  3 
AAS 1 
 Fanconi Syndrome 1 
Ematodermic Neoplasia 1 
BAL 1 
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     Table 5. Transplants characteristics 
Graft Type 
Bone Marrow 19 
Peripheral Blood Progenitor Cells 70 
Conditioning 
Busilvex-Ciclofosfamide  15 
Busilvex-Fludarabine  15 
Fludarabine-Melphalan  4 
Thiotepa + others 7 
Ciclofosfamide + others  14 
Endoxan  4 
Unknown 32 
TBI  6 
ATG  12 
Donor/ Recipient HLA-allele matching at  
A, B, C, DRB1 and DQB1 
10/10 32 
9/10 33 
≤8/10 24 
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3.2 KIR genotyping 
The donors’ DNA, which has already been typed for HLA, has been preserved in 
our bio-bank; about 80% of the samples is still available. The DNA was extracted from 
buffy coat or whole blood by the automatic extractor Maxwell 16 (Promega) or by the 
salting out method.  
Typing of KIR genes was performed with PCR-SSO Luminex, the same method 
already used in our laboratory to type the HLA genes. The kit used for KIR genes 
typing was the SSO KIR Genotyping Test (One Lambda Inc., Canoga Park, CA) and the 
method was performed in accordance with the manufacturer's instructions. Luminex 
technology is based on the ability to soundly measure multiple analytes simultaneously 
in a single reaction and this is done through the use of plastic microbeads 
(microspheres), which are color-coded with two fluorescent dyes so as to emit two 
different wave lengths in red and infrared. In this way a set of over 100 different 
microspheres can be created. The microspheres represent the solid support of 
oligonucleotide probes which can bind amplified DNA,vwhich is labeled with a 
fluorescent labeled reporter. Subsequently, the microbeads are acquired by the Luminex 
machine through a precision sheath fluid system, based on classical flow cytometry, 
which aligns them in single file, where they pass through two lasers: the red laser 
excites the colours inside the microbeads to identify which microbead is currently being 
read while the green laser excites the colour on the microbead surface, i.e. the labeled 
reporter tag. Finally, the color signals are detected by an advanced optical system, and 
the signals are processed into data for each reaction [16]. 
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The PCR reaction using specific primers for the KIR genes is first conducted 
with a specific amplification program via the GeneAmp PCR System 9700 (Applied 
Biosystems, Forster City, CA). The amplification products are tested by electrophoresis 
on 2% agarose gel and then observed and photographed under a UV trans illuminator. 
The PCR product is biotinylated, which allows it to be detected by strepavidin-
conjugated with PE (SAPE). Subsequently, the PCR products are denatured facilitating 
rehybridization to complementary DNA probes bound to the microbeads with a specific 
sequence (SSO) to recognize the polymorphic sites within KIR genes. The amplified 
products which have undergone a hybridization reaction are labeled with streptavidin 
conjugated with R- Phycoerythrin and then acquired with the flow cytometry system 
LABScanTM 100 Luminex (Figure 5), which measures the fluorescence intensity of 
phycoerythrin on each microsphere (The steps of PCR-SSO method are summarized in 
Figure 4). The data are then analyzed with the software HLA –Fusion (Figure 6). 
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Figure 4. The steps of  PCR-SSO (Sequence Specific Oligonucleotide). 
 
 
 
              
Figure 5.  The Luminex  machine: the microbeads are transported into the Luminex analyzer by using a 
precision sheath fluid stream to align them in single file, where they pass through two lasers, similarly to 
classical flow cytometry. The red laser excites the colours inside the microbeads to identify which 
microbead is currently being read. The green laser excites the colour on the microbead surface, i.e. the 
labeled reporter tag. Finally, the color signals are detected by an advanced optical system, and the signals 
are processed into data for each reaction. 
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Figure 6. Fusion Software is used to analyze results of PCR-SSO Luminex.  
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4. RESULTS 
4.1 Donors classification 
We typed KIR genes of the 89 selected donors of the transplanted patients and 
we classified them on the basis of the KIR haplotypes possessed.  
Figure 7, 8 and 9 are reports of three donors KIR typing: in the first case there is 
KIR2DS4 and so it is Group A Haplotype and the donor KIR B status is Neutral; in the 
second one there are KIR2DS1 and KIR2DS3 and so it is Group B/x Haplotype and the 
donor KIR B status is Better; in the third there is KIR2DS2 and so it is Group B/x 
Haplotype and the donor KIR B status is Best. 
KIR gene frequency among the donor population was similar to that of 
published data [17, 18]: no. 30 (33,7%) donors were A/A and no. 59 (66,3 %) were B/x.  
Then we classified them using the Donor KIR B Content Score Calculator at 
http://www.ebi.ac.uk/ipd/kir/: no. 63 (70,8%) donors were neutral, no. 18 (20,2%) 
Better and no. 8 (9%) Best. In our analysis we combined the Better and Best groups to 
form the KIR Better/Best donor group (with two or more B motifs). The classification 
of the donors in accordance with the KIR B content score is summarized in Table 6. 
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Figure 7. A report of a donor KIR typing: in this case there is KIR2DS4 and so it is Group A Haplotype 
and the donor KIR B status is Neutral. 
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Figure 8. A report of a donor KIR typing: in this sample there are KIR2DS1 and KIR2DS3 and so it is 
Group B/x Haplotype and the donor KIR B status is Better. 
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Figure 9. A report of a donor KIR typing: in this sample there is KIR2DS2 and so it is Group B/x 
Haplotype and the donor KIR B status is Best. 
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4.2 Clinical outcome analysis 
4.2.1 Overall Survival, Relapse and Disease Free Survival 
The overall survival-rate was analyzed generating the Kaplan-Meyer curves, 
using the GraphPad6 Demo software; the data were compared using the Log-Rank Test 
95%CI.  
We observed no significant difference in the overall survival-rate of those 
patients transplanted from A/A donor and those from B/x donor, while we found a 
better overall survival-rate in the AML recipients, HLA mismatched with the donor, 
when the donor KIR B content status is Best/Better (37% vs 18% at three years Log-
Rank-Test P=0,028) (Figure 10), whereas there is no beneficial effect in recipients with 
other haematological malignancies (Figure 11). 
Moreover, we observed that AML recipients, whose Donors KIR B status was 
Best/Better, had a lower incidence of relapse than patients whose Donors KIR B status 
was Neutral (36% vs 58%) (Figure 12 and 13) and a better Disease Free Survival-rate 
(58% vs 38% at three years P=0,1) (Figure 14). 
We have not been able to make a comparison of the 10/10 HLA matched AML 
recipients because only one donor was Best/Better. 
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Figure 10. Overall Survival of AML recipients of HLA mismatched MUD transplants. 
 
 
 
 
 
                   Figure 11. Overall Survival of recipients with other hematologic malignancies of HLA       
mismatched MUD transplants. 
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Figure 12. Disease Free Survival-rate of AML recipients of HLA mismatched MUD transplants. 
 
 
Figure 13. Incidence of Relapse in AML Recipients of Best/Better MUD. 
 
 
Figure 14. Disease Free Survival-rate of AML recipients of HLA mismatched MUD transplants. 
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4.2.2 aGvHD 
The incidence of aGvHD in AML patients was: 55,17% (no. 16/29) of no 
aGvHD, 41,38% (no. 12/29) of aGvHD grade I II, 3,45% (no. 1/29) of aGvHD grade III 
IV (Figure 15).  
We observed that AML recipients, whose Donors KIR B status was Best/Better, 
had more incidence of aGvHD grade I II than patients whose Donors KIR B status was 
Neutral: 70% vs 26% (Figure 16 and 17). 
Actually, as regards patients who have aGvHD grade I II, this results in a 
beneficial effect on the overall survival-rate. In fact, we observed that patients with 
aGvHD grade I II had a significantly better overall survival-rate than patients with 
noGvHD (51,6% vs 38% at three years P=0,04) (Figure 18). This agrees with those 
studies [4] showing that patients with aGvHD I II have a better overall survival-rate and 
a lower rate of relapse due to a GvL effect. 
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 Figure 15. The incidence of aGvHD in AML patients 
 
 
Figure 16.  Incidence of aGvHD in AML Recipients of Neutral MUD. 
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 Figure 17. Incidence of aGvHD in AML Recipients of Best/Better MUD. 
 
 Figure 18. Patients with aGvHD grade I II had a significantly better overall survival than 
patients with noGvHD (51,6% vs 38% at trhee years P=0,04) 
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5. Discussion 
In recent years, various studies have shown that the beneficial GvL effect 
promoted by allo-reactive NK cells derived from the donor can improve the outcome of 
the HSCT from Haploidentical, Unrelated and HLA identical sibling donors. In 
particular Cooley S. et al. [12] have demonstrated that AML patients who received HSC 
transplants from unrelated Group B KIR haplotypes donors, had a better outcome after 
transplant because the haplotypes of Group B have a larger number of activating 
receptors, and this translates into better anti-leukemic activity. In a subsequent study 
[13], they found that some particular KIR receptors had a stronger effect and they 
defined three categories of donors: Neutral (none or one KIR B motifs), Better (two or 
more B motifs without KIR Cen B/B) and Best (two or more B motifs with KIR Cen 
B/B). 
In our study we analyzed the impact of the donor KIR B status on the outcome 
of the unrelated HSC transplants performed in our center.  We observed no significant 
difference in overall survival of those patients transplanted from A/A donor and those 
from B/x donor, probably because we do not have a large enough cohort of transplanted 
patients, and we were not able to make a meaningful comparison; on the other hand, 
despite this small cohort of patients, we have been able to observe the powerful effect of 
the Best/Better Donor KIR B status in the AML recipients HLA mismatched with the 
donor. They had a significantly better overall survival-rate if the donor KIR B content 
status was Best/Better and they also had a higher incidence of aGvHD grade I and II, 
and had a lower rate of relapse due to GvL effects.  
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Even though our cohort was small, our results confirmed that the presence of 
more activator KIR genes in donors can improve the outcome of UDHSC HLA 
mismatched transplants in AML recipients whereas there is no benefit in recipients with 
other hematologic malignancies. Our next target is to increase the number of cases by 
adding the other transplants performed and to study the effect of GvL in relapse in the 
same patients. 
In any case, our results confirm that NK cells derived from donors with two or 
more KIR B motifs, have an improved ability to kill residual leukemic blasts in AML 
recipients of UDHSCT. As a consequence of this, the KIR genotype of the donor is 
another important criterion to be taken into account for the choice of the best possible 
donor in unrelated, sibling and haploidentical HSC transplant settings, together with all 
the other important factors, such as HLA matching, CMV status, blood group, age and 
gender. Future studies should be aimed at finding the right alloreactive subsets among 
donor NK cell repertoires, opening up the possibility for successful NK cell-based 
immunotherapy. Antileukemic NK cells, either allogeneic or unlicensed autologous NK 
cells, emerge as a feasible therapy option and might improve the clinical outcome in 
myeloid leukemia. 
 
 
 
 
Note: This work has been accepted for publication in the book “Hematopoietic Stem Cells” with the Title 
"Impact of the Donor KIR Genotype on the Clinical Outcome of Hematopoietic Stem Cell Unrelated 
Transplants: a single center experience", ISBN 978-953-51-4937-8. 
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